Buyers, channels and consolidation

Buyers

• Pharma preclinical safety, DMPK and translational groups. The largest budget, mostly spent on internal decisions. Enterprise sales cycles into pharma R&D are often cited at 9 to 18 months.
• CROs. Increasingly the channel and sometimes the buyer. Charles River runs its Alternative Methods Advancement Project, formed a NAMs advisory board and is buying PathoQuest. IQVIA agreed to buy Charles River's in vitro discovery sites in February 2026.
• Government. NIH (Complement-ARIE, ORIVA), ARPA-H (CATALYST, up to $125M) and UK and EU programs fund development and validation.
• Chemicals, cosmetics and agrochemicals. Regulation drives demand: EU cosmetics rules, REACH, TSCA, FIFRA and the UK targets.

How incumbents frame it

Charles River's leadership calls the shift an evolution and expects hybrid approaches. In 2025 it put about $50M of annual revenue at risk from FDA's NAM push, with no immediate impact expected.

Consolidation

Strategic acquirers are buying NAM assets:

Year	Buyer	Target
2024	Merck KGaA	HUB Organoids
2024	Quris-AI	Nortis
2025	Sartorius	MatTek ($80M)
2025	InSphero	DOPPL
2026	IQVIA	Charles River discovery sites (~$145M, agreed)
2026	Charles River	PathoQuest
2026	InSphero	PhenoVista
2026	Bruker	MIMETAS (majority)

Most prices are undisclosed. The disclosed ones are modest: MatTek sold for $80M on more than $20M of sales.